Fox Hill Wealth Management Takes $1.60 Million Position in DaVita Inc. $DVA

Fox Hill Wealth Management acquired a new stake in DaVita Inc. (NYSE:DVA) in the 2nd quarter, Holdings Channel reports. The fund acquired 7,212 shares of the company’s stock, valued at approximately $1,605,000.

Several other large investors also recently bought and sold shares of the stock. Root Financial Partners LLC increased its stake in DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after purchasing an additional 105 shares in the last quarter. Caitlin John LLC purchased a new stake in shares of DaVita during the fourth quarter valued at $34,000. Sankala Group LLC purchased a new stake in shares of DaVita during the fourth quarter valued at $39,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita in the 2nd quarter valued at $43,000. Finally, Kestra Advisory Services LLC purchased a new position in DaVita in the 4th quarter worth $45,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DVA. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Truist Financial dropped their target price on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Finally, Raymond James Financial set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $221.75.

DaVita Stock Performance

NYSE DVA opened at $180.72 on Friday. The firm has a market capitalization of $11.53 billion, a P/E ratio of 14.79, a PEG ratio of 0.46 and a beta of 0.88. The stock has a 50-day simple moving average of $211.96 and a two-hundred day simple moving average of $183.05. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.90% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.